Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Enliven Therapeutics Provides Corporate Update On Financing, Expansion Of Board And Leadership Team
PUBLIC · ELVNJan 19, 2022•over 4 years ago
Round Type
Funding Round
BoulderBiotechnologyHealthcareHealth CareScience And EngineeringTherapeutics
Description
Enliven Therapeutics, Inc. ("Enliven" or the "Company"), a precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today provided a corporate update on the close of an $85 million Series B financing, additions to the Board of Directors, and expansion of the Company's leadership team.
Company Information
Company
Enliven Therapeutics
Location
Boulder, Colorado, United States
About
Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer live not only longer, but better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being. Enliven’s discovery process combines deep insights from clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies.
Don't miss Enliven Therapeutics's next move
Get an email the moment Enliven Therapeutics raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
Suggested for you
1 contact
Verified contacts17 people are listed at Enliven Therapeutics. We don't have their email yet.
Predictive Intelligence
Strategic
ML-powered predictions for Enliven Therapeutics's next move
BoulderBiotechnologyHealthcareHealth CareScience And EngineeringTherapeutics